4.1 Review

Mechanisms and mediators of pulmonary fibrosis

期刊

CRITICAL REVIEWS IN IMMUNOLOGY
卷 25, 期 6, 页码 429-463

出版社

BEGELL HOUSE INC
DOI: 10.1615/CritRevImmunol.v25.i6.10

关键词

fibrosis; chemokines; cytokine; pulmonary; fibroblast

资金

  1. NCI NIH HHS [CA87879] Funding Source: Medline
  2. NHLBI NIH HHS [HL04493, HL082744, P50HL67665, HL66027] Funding Source: Medline
  3. NATIONAL CANCER INSTITUTE [R01CA087879] Funding Source: NIH RePORTER
  4. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004493, R01HL066027, P50HL067665] Funding Source: NIH RePORTER

向作者/读者索取更多资源

The mechanisms of pulmonary fibrosis are complex, and several hypotheses have been put forward to explain how fibrosis develops. It was long thought that inflammation was a key event in the process; however, this has recently been challenged. The inflammation hypothesis has led to the description of numerous inflammatory and profibrotic mediators in the pathogenesis of fibrosis. Inhibition of inflammation can attenuate fibrosis in animal models but is less successful in humans. More recently, an important role for epithelial injury, circulating mesenchymal precursor cells, epithelial-to-mesenchymal transition, and vascular remodeling have been described in various models of fibrosis. Many of the classic inflammatory and profibrotic mediators are important in these processes, as well. The development of effective therapies will require the understanding of the complex interplay of the various mediators and the mechanisms of remodeling.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据